Opinion|Videos|March 25, 2024
Exciting New Approaches in Metastatic Urothelial Carcinoma
Experts on bladder cancer discuss exciting new agents and treatment strategies and where they can potentially fit into urothelial cancer treatment paradigms.
Advertisement
Episodes in this series
Advertisement
Related to this article
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
2
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
3
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
4
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
5